Johnson & Johnson's Spravato, an inhaled esketamine treatment approved in 2019, established the clinical infrastructure that Compass Pathways plans to utilize for COMP360.

From the articleHow J&J paved the way for Compass’ coming psychedelic drug launchAlso in Deep dive: Psychedelics back on FDA’s doorstep